FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
insight
/
details

Optimizing Diagnostic Gene Panels for Effective Genetic Disorder Diagnosis

NextEdge Admin

01 May 2024

2 min 45 sec

A well-designed diagnostic gene panel is essential for effectively diagnosing genetic disorders while minimizing unnecessary testing and potential patient anxiety. Such panels should prioritize maximizing clinical sensitivity and specificity while also considering clinical validity and utility.

Clinical sensitivity, determined by both biomedical knowledge and technical capabilities, ensures that the panel can accurately detect relevant gene-disease associations. This involves including all genes associated with the disorder to maximize sensitivity while minimizing variants of uncertain significance (VUS). However, careful consideration is needed to balance comprehensive testing with the risk of generating large numbers of VUS, which can complicate patient management.

Clinical specificity is crucial for matching a patient’s clinical features with the appropriate genes, thereby reducing the likelihood of detecting irrelevant variants and minimizing VUS. Gene panels should be tailored to specific phenotypes to enhance specificity, and for disorders with extreme genetic heterogeneity, broader tests like exome or genome sequencing may be more suitable initially.

Clinical validity is crucial for establishing the strength of evidence for gene-disease associations. Laboratories must regularly evaluate the evidence and adjust variant classifications, accordingly, ensuring that variants are interpreted accurately based on the available evidence.

In constructing diagnostic gene panels, it’s essential to include genes with strong evidence for the clinical indication while also considering the intended use of the test (e.g., diagnostic, predictive, or carrier screening). Additionally, panels should be periodically updated to incorporate new gene discoveries and evidence, with clear communication of any genes of uncertain significance included in the test description.

Ultimately, a well-designed diagnostic gene panel optimizes clinical sensitivity and specificity while ensuring accurate and clinically relevant variant interpretation, thus facilitating effective diagnosis and management of genetic disorders.